IMPRIMIS PHARMACEUTICALS

NASDAQ: IMMY

MARK L. BAUM

MARCH 2015

2

SAFE HARBOR

This presentation contains express "forward-looking statements" as defined in the Private

Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-

looking statements. These statements are based on current expectations of future events. If

underlying assumptions prove inaccurate or known or unknown risks or uncertainties

materialize, actual results could vary materially from the Company’s expectations and

projections. Some of these risks and uncertainties include, but are not limited to: the

Company’s ability to make commercially available its formulations and technologies in a

timely manner or at all; market acceptance of the Company’s formulations and challenges

related to the marketing of the Company’s formulations; its ability to obtain intellectual

property protection for its assets; its ability to accurately estimate its expenses and cash

burn, and raise additional funds when necessary; its ability to generate profits from sales of

its formulations; risks related to research and development activities; the projected size of

the potential market for its technologies and formulations; unexpected data, safety and

technical issues; regulatory and market developments impacting compounding pharmacies,

outsourcing facilities and the pharmaceutical industry; competition; and market conditions.

More detailed information about the Company and the risk factors that may affect the

realization of forward-looking statements is set forth in the Company’s filings with the

Securities and Exchange Commission, including its Annual Reports on Form 10-K and its

Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of

charge on the SEC’s web site at www.sec.gov. All forward-looking statements are qualified

in their entirety by this cautionary statement. You are cautioned not to place undue reliance

on these forward-looking statements, which speak only as of the date hereof. Imprimis

expressly disclaims any intent or obligation to update these forward-looking statements

except as required by law.

3

STATE OF DRUG DEVELOPMENT

Of 220 drugs approved over the past decade

for publicly traded companies, the companies

that invented 3 or more medicines spent an

average $4.3 billion in R&D per drug. (Sept ’13)

“Eroom’s law – that’s Moore’s law backward –

observes that the number of new drugs

approved per billion dollars spent on R&D has

halved every nine years since 1950.”

4

MARKET POSITIONING

Low Risk

Low Margin

High Risk

High Margin

Lower Risk | Higher Margin

5

CORE SSP TECHNOLOGYTM

6

TABLE OF CONTENTS

OPHTHALMOLOGY BUSINESS

DROPLESS THERAPYTM INJECTABLES

LESS DROPSTM TOPICALS

UROLOGY BUSINESS

HEP-LIDO-A (HLA)

IMPRIMISRXTM

COMPOUNDING PHARMACIES

OUTSOURCING FACILITIES

OPHTHALMOLOGY BUSINESS

DROPLESS THERAPYTM INJECTABLES

LESS DROPSTM TOPICALS

7

8

CATARACT SURGERY MARKET

In Need of a Solution

Standard of care is eye drop therapy

$1B+ spent on eye drops in the US

Eye drops = The Three C’s:

Cost, Compliance, Call Backs

Dissatisfaction with eye drops

How do you reduce reliance on eye drops?

9

POST-OP SUMMARY

THE EYE DROP JOURNEY

PATIENT PROFILE SCHEDULING SURGERY DAY

80 years old

Arthritis

Scoliosis

Lives alone

Social Security

Rxs for multiple eye drops Pharmacy switched Rxs

Cannot afford QD and BID drops (on Rx)

Patient brings QID generic drops

Difficulty administering

Confusion on regimen

Runs out; no refills

Higher cost to the patient

Compliance concerns

Calls to office staff

Risk of endophthalmitis, inflammation and CME

10

POST-OP SUMMARY

PATIENT PROFILE SCHEDULING SURGERY DAY

THE DROPLESS JOURNEY

SURGERY DAY

Dropless Therapy injected intravitreally

Eye looks quiet

No infection

No inflammation

Patient saves money

Patient happy

No compliance concerns

80 years old

Arthritis

Scoliosis

Lives alone

Social Security

No eye drop Rxs

Informed about Dropless Therapy

11

Enabled by SSP Technology™

Ocular injection platform

Antibiotic and anti-inflammatory

prophylaxis

Significant cost savings

Eliminates compliance issues

Decreases staff time

Patients and MDs prefer Dropless

DROPLESS THERAPYTM

12

LESSDROPSTM

PLATFORM

Enabled by SSP Technology™

Combination drop platform

Antibiotic + Steroid

NSAID + Steroid

Triple Drop™

50% fewer drops

Lower cost (up to 75% savings)

Better compliance

Reimbursable

13

LASIK and Refractive Surgery

>50% of Americans require vision correction

43M are candidates for refractive surgery (US)

>35M LASIK performed since 1999 (Global)

>700,000 LASIK procedures annually (US)

OCULAR SURGERY MARKET

Cataract Surgery

>24M Americans over age 40 have cataracts

3.6M cataract surgeries performed in 2013 (US)

4.3M surgeries expected in 2017

14

GO DROPLESSTM

CAMPAIGN

Since Go Dropless Launch in April 2014

>50 media segments since launch

Available in 41 states

>35,000 surgeries since launch

>240 prescribing MDs and growing

Non-human and outside US opportunities

Cannula companies supporting Dropless

15

HEALTHCARE SAVINGS POTENTIAL

Drop Therapy*

Dropless Therapy

TOTAL COST

Dropless Therapy = >$1 Billion/Yr Savings

COST PER THERAPY

$482

$100

$1.35B

$280M

2.8M of estimated 3.6M US cataract procedures are Medicare recipients.

*Based on survey of Walmart.com in Nov. 2014 for Vigamox ($128.79), Durezol ($194.84) and Ilevro ($159.28). Total: $482.91.

UROLOGY BUSINESS

HEP-LIDO-A (HLA)

16

17

INTERSTITIAL CYSTITIS (IC)

Also known as painful bladder syndrome

Chronic disease; pain; frequent urination

Recurring flares (3-7 days); average 4/yr

Severity, duration, and frequency varies

>5M have IC (Journal of Urology)

85% with IC are women

Elmiron® is only FDA-approved oral

3-6 months to starting working

Compliance issues

Reported side effects

18

HLA FORMULATION

Heparin + alkalinized lidocaine

Developed by inventor of Elmiron®

Patented through 2026

Exclusive license in April 2015

Studies reported immediate relief

>80K Rxs (2014); est. $5.5M

Defeat ICTM launched Q1-2015

Reimbursed by insurance; $60-$70

HLA and $150-$180 for procedure

19

MARKET OPPORTUNITY

Market opportunity est. $4.8B/yr

Assumptions:

$60 per HLA formulation

5M US patients

4 flares/year

4 instillations per flare

IMPRIMISRXTM

COMPOUNDING PHARMACIES

OUTSOURCING FACILITIES

20

21

IMPRIMISRX™ PHARMACIES

503A of the FDCA

State pharmacy licensing boards

PCAB-accredited

Licensed in 41 states

National redundant operations (2015)

(Acquired April 1, 2014)

(Acquired January 1, 2015)

22

OUTSOURCING FACILITIES

New 503B outsourcing facility,

Roxbury, NJ 8,600 sq. feet

cGMP production standards

Focus on flagship formulations

Interstate distribution

No individual patient prescription

(Acquired April 1, 2014)

(Acquired January 1, 2015)

23

LAND AND EXPAND STRATEGY

Investing in relationship-building

“Land” by solving pain points

“Expand” with generic “add-ons”

Strong margins on proprietary

and non-proprietary offerings

Providing A+ customer service

(Acquired April 1, 2014)

(Acquired January 1, 2015)

24

CONCLUSION

Disruptive and capital efficient business model

Rapidly growing ophthalmology franchise

Urology business expected to accelerate growth

Valuable intellectual property portfolio

Opportunity to expand revenues and margins with

complementary offerings

Potential opportunist regulatory environment

Infrastructure in place to support growth

25

COMPANY PROFILE

Trading Symbol: NASDAQ: IMMY

Current Price per Share (3-20-15): $7.91

Market Cap: $74 Million

52-Wk Range: $4.71 - $9.24

Number of Employees: 64

Headquarters: San Diego, CA

503A Pharmacies: Randolph, NJ and Irvine, CA

503B Outsourcing Facility: Roxbury, NJ (under construction)

Financial Info:

No preferred shares or convertible debt; No senior debt

Cash position - $8.2 million as of 12-31-2014

2014 revenues $1.7 million

CONTACT US

Imprimis Pharmaceuticals

(NASDAQ: IMMY)

12264 El Camino Real, #350

San Diego, CA 92130

858-704-4040

26

Imprimis Pharmaceuticals

(NASDAQ: IMMY)

12264 El Camino Real, #350

San Diego, CA 92130

858-704-4040

www.imprimispharma.com